Cancer Institute A national cancer institute
designated cancer center

Willard ("Bill") E. Fee, Jr.

Publication Details

  • 24-HOUR INFUSION OF CIS-PLATINUM IN HEAD AND NECK CANCERS CANCER Jacobs, C., Bertino, J. R., Goffinet, D. R., Fee, W. E., Goode, R. L. 1978; 42 (5): 2135-2140

    Abstract:

    Eighteen patients with advanced squamous cell cancer of the head and neck were treated with cis-diamminedichloroplatinum in a 24-hour infusion. The most frequent dose used was 80 mg/m2 repeated every three weeks. Six were treated preoperatively for Stage III or IV disease, and twelve were treated for recurrent disease. The overall response rate was 72% with one complete remission, greater than 50% regression in six patients, and 25--50% regression in six patients. Toxicity was minimal: creatinine greater than 2 in 6% of courses, leukopenia in 9%, anemia in 29%, vomiting in 76%, and documented minimal hearing loss in one patient. Plasma and urine platinum levels during infusion are presented. The dosage of 80 mg/m2 administered over 24 hours gives a response rate in head and neck cancers equivalent to that reported with higher doses given by rapid infusion, and toxicity is minimal.

    View details for Web of Science ID A1978FY61800007

    View details for PubMedID 719601

Stanford Medicine Resources:

Footer Links: